Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Besremi + Ruxolitinib in Myelofibrosis
NCT06770842Phase 2Recruiting
- Sponsor
- The University of Hong Kong
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ropeginterferon alfa-2b in myelofibrosis (MF), sponsored by The University of Hong Kong. Started Mar 2025; status: recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06770842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06770842.